Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Author(s)
Smyth E1, Sibiga A2, Nehdi AN2, Krishna A3, Kim K2, Coaquira Castro J4, Priedane E5, Zhan L4
1Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK, 2EVERSANA, Burlington, ON, Canada, 3EVERSANA India Private Limited, Mumbai, MH, India, 4BeiGene USA, Inc., Emeryville, CA, USA, 5BeiGene UK, Ltd., London, LON, UK
Presentation Documents
CONCLUSIONS:
This SLR provides a comprehensive overview of current evidence for burden of illness in 1L ESCC. These data provide valuable insights to payers for supporting reimbursement in worldwide markets.Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
CO9
Topic
Clinical Outcomes, Economic Evaluation, Study Approaches
Topic Subcategory
Clinical Outcomes Assessment, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Literature Review & Synthesis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology